Diabetes Medicines — Medication Guide, Uses & Safety — Uses, Dosage & Side Effects | MyMedicPlus

Diabetes medicines are a broad group of antidiabetic drugs used primarily in type 2 diabetes mellitus (T2DM) to control blood glucose levels and reduce the risk of serious long-term complications — including heart disease, stroke, chronic kidney disease, retinopathy, neuropathy, and foot complications that can lead to amputation. Type 2 diabetes affects over 500 million people worldwide and is characterized by insulin resistance and progressive failure of pancreatic beta cell function. Metformin (a biguanide) is the established first-line oral drug for most patients with type 2 diabetes, recommended by all major diabetes guidelines due to its efficacy, safety, and low cost. Newer drug classes have transformed diabetes management: GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) reduce blood glucose, promote significant weight loss, and reduce cardiovascular events; SGLT-2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) lower glucose through urinary excretion and provide proven benefits in heart failure and chronic kidney disease. Diabetes medicines are prescription-only and require individualized management by a diabetes specialist (diabetologist/endocrinologist), general practitioner, or trained diabetes nurse. Regular HbA1c monitoring, blood pressure control, and lipid management are integral components of comprehensive diabetes care.

Antidiabetic medicines are used primarily to control blood glucose (HbA1c) in type 2 diabetes and prevent or delay the onset of its serious microvascular and macrovascular complications. Metformin is the universal first-line agent for type 2 diabetes. Second-line therapy is guided by individual patient factors: for patients with established cardiovascular disease (heart attack, stroke, peripheral artery disease) or high cardiovascular risk, GLP-1 agonists (semaglutide/Ozempic, liraglutide/Victoza) or SGLT-2 inhibitors (empagliflozin/Jardiance, dapagliflozin/Forxiga, canagliflozin/Invokana) are preferred due to their proven cardiovascular mortality benefits. For patients with chronic kidney disease and proteinuria, dapagliflozin and empagliflozin have proven renal-protective benefits independent of blood glucose. For patients with heart failure (particularly heart failure with reduced ejection fraction), SGLT-2 inhibitors are strongly recommended. DPP-4 inhibitors (sitagliptin/Januvia, saxagliptin, vildagliptin, alogliptin) are weight-neutral and well-tolerated add-on options. Sulfonylureas (gliclazide, glibenclamide, glipizide, glimepiride) are inexpensive and effective but carry hypoglycemia risk. Thiazolidinediones (pioglitazone) improve insulin sensitivity but can cause fluid retention and bone fracture risk. GLP-1 agonists (semaglutide/Wegovy, liraglutide/Saxenda) are also FDA-approved for chronic weight management in adults with obesity.

Each diabetes drug class works through a distinct mechanism targeting different aspects of blood glucose regulation. Metformin primarily reduces excessive hepatic glucose production (gluconeogenesis) by activating AMPK, and also improves peripheral insulin sensitivity in muscle and fat cells — it does not stimulate insulin secretion and therefore does not cause hypoglycemia. Sulfonylureas (gliclazide, glibenclamide) bind to ATP-sensitive potassium channels on pancreatic beta cells, stimulating insulin secretion independent of blood glucose levels — explaining their hypoglycemia risk. GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) mimic the gut hormone GLP-1 — they stimulate glucose-dependent insulin secretion, suppress glucagon (which raises blood glucose), slow gastric emptying (reducing postprandial glucose spikes), and act on the hypothalamus to reduce appetite and food intake, leading to significant weight loss of 5–15% or more. SGLT-2 inhibitors (empagliflozin, dapagliflozin) block the sodium-glucose cotransporter 2 (SGLT-2) in the renal proximal tubule, which normally reabsorbs approximately 90% of filtered glucose back into the bloodstream — blocking it causes glucose excretion in the urine, lowering blood glucose while also reducing blood pressure and weight. DPP-4 inhibitors (sitagliptin, vildagliptin) inhibit the enzyme dipeptidyl peptidase-4 that normally degrades natural GLP-1 and GIP incretin hormones, extending their glucose-lowering effect — they are weight-neutral and have a low hypoglycemia risk.

Metformin: initiated at 500 mg once or twice daily with food to minimize GI side effects, typically increased to 1000 mg twice daily (maximum 2000–2550 mg/day in divided doses) over 4–8 weeks. Gliclazide (sulfonylurea): 40–80 mg once daily with breakfast, up to 320 mg daily in divided doses. Gliclazide MR: 30–120 mg once daily. Semaglutide (GLP-1 — oral, Rybelsus): 3 mg once daily for 30 days, then 7 mg, then 14 mg — taken on an empty stomach 30 minutes before food. Semaglutide (injectable, Ozempic): 0.25 mg weekly for 4 weeks, then 0.5 mg weekly, up to 2 mg weekly. Empagliflozin (SGLT-2): 10 mg once daily (for heart failure: 10 mg daily regardless of diabetes status); may increase to 25 mg for additional glucose lowering. Sitagliptin (DPP-4): 100 mg once daily (reduce to 50 mg if eGFR 30–50; 25 mg if eGFR below 30). Pioglitazone: 15–45 mg once daily. All antidiabetic drug doses require individualized prescription, titration, and regular monitoring of HbA1c, kidney function (eGFR), and blood glucose. Never self-adjust diabetes medicines without medical supervision.

Metformin: the most common side effects are gastrointestinal — nausea, diarrhea, abdominal cramping, and metallic taste — affecting up to 30% of users initially; these typically improve over 2–4 weeks, especially when dose is escalated slowly and taken with food. Rare but serious: lactic acidosis (dangerously elevated blood lactate levels) in patients with severely impaired kidney function, liver failure, or acute illness — estimated incidence extremely low (approximately 3 cases per 100,000 patient-years) with correct prescribing. Long-term metformin use can reduce vitamin B12 absorption — annual B12 level monitoring is recommended. Sulfonylureas: the most significant risk is hypoglycemia (low blood glucose) — presenting as shakiness, sweating, palpitations, confusion, or in severe cases seizures or loss of consciousness. The risk is higher with longer-acting sulfonylureas (glibenclamide), in the elderly, in those skipping meals, or in those with kidney impairment. Weight gain of 2–5 kg is typical with sulfonylureas. GLP-1 receptor agonists: common adverse effects include nausea and vomiting (30–40% initially, usually decreasing after 4–8 weeks), diarrhea, and injection site reactions. Pancreatitis has been reported — discontinue immediately if persistent severe abdominal pain develops. Medullary thyroid carcinoma concern exists in rodents; avoid with personal or family history of MEN2 syndrome or familial medullary thyroid carcinoma. SGLT-2 inhibitors: genital mycotic infections (candidal thrush — in approximately 10% of female users, 5% male), urinary tract infections, increased urination and thirst, and mild blood pressure lowering. Rare but serious: euglycemic diabetic ketoacidosis (DKA — metabolic acidosis even with near-normal blood glucose levels, particularly with fasting, surgical procedures, or significant carbohydrate restriction); Fournier's gangrene (necrotizing fasciitis of the perineum — very rare). SGLT-2 inhibitors should be withheld for at least 3 days before major surgery or during serious acute illness. DPP-4 inhibitors: generally very well tolerated; joint pain (arthralgia) occurs in approximately 1–3%; rare risk of acute pancreatitis.

Metformin is contraindicated when eGFR (estimated glomerular filtration rate) falls below 30 mL/min/1.73m² due to lactic acidosis risk, and must be used with caution and dose reduction when eGFR is 30–45. Metformin must be temporarily withheld 24–48 hours before radiological contrast procedures and not restarted until kidney function is confirmed stable 48 hours afterward. Sulfonylureas carry a clinically significant hypoglycemia risk — all patients must be educated to recognize and treat hypoglycemia promptly (oral fast-acting carbohydrates — glucose gel, glucose tablets, fruit juice — 15 g, repeat after 15 minutes if not improved; call emergency services for severe hypoglycemia with loss of consciousness). Hypoglycemia risk is amplified by alcohol, missed meals, unusual exercise, and drug interactions with NSAIDs, fluconazole, and sulphonamide antibiotics. GLP-1 agonists: the FDA requires a black-box warning regarding the risk of medullary thyroid carcinoma — contraindicated with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2). SGLT-2 inhibitors carry an FDA warning for increased risk of lower limb amputations (particularly canagliflozin — CANVAS trial data) and bone fractures (canagliflozin). They should be avoided in patients with recurrent UTIs or a history of Fournier's gangrene. Key drug interactions: alcohol significantly increases hypoglycemia risk with sulfonylureas and insulin; NSAIDs can mask hypoglycemia symptoms; rifampicin reduces the effectiveness of sulfonylureas by inducing CYP2C9. All patients with type 2 diabetes should also be managed for cardiovascular risk factors (blood pressure, cholesterol, smoking, weight) — a holistic multifactorial approach. Never self-adjust diabetes medicines without consulting your diabetes care team.